Table 1.
Distribution of all patients by presence or absence of bcl-2 and bax data (n = 456)
| bcl-2
|
bax
|
|||||
|---|---|---|---|---|---|---|
| Characteristics | Presence (n = 119) | Absence (n = 337) | p value* | Presence (n = 104) | Absence (n = 352) | p value* |
| Age | ||||||
| <75 | 86 (72%) | 239 (71%) | 0.78 | 82 (79%) | 243 (69%) | 0.052 |
| ≥75 | 33 (28%) | 98 (29%) | 22 (21%) | 109 (31%) | ||
| GLSC# | ||||||
| 2–6 | 31 (26%) | 98 (32%) | 0.29 | 27 (26%) | 102 (31%) | 0.33 |
| 7–10 | 87 (74%) | 213 (68%) | 76 (74%) | 224 (69%) | ||
| T-Stage | ||||||
| T2 | 33 (28%) | 104 (31%) | 0.52 | 24 (23%) | 113 (32%) | 0.08 |
| T3 | 86 (72%) | 233 (69%) | 80 (77%) | 239 (68%) | ||
| Assigned Treatment | ||||||
| RT Alone | 67 (56%) | 163 (48%) | 0.14 | 57 (55%) | 173 (49%) | 0.31 |
| RT+STAD | 52 (44%) | 174 (52%) | 47 (45%) | 179 (51%) | ||
Abbreviations: GLSC = Gleason Score; RT = radiation therapy; STAD = short term androgen deprivation.
*
Chi-square statistics.
#
Gleason score is unknown in 1 patient with bcl-2/bax data and in 26 patients with absent bcl-2/bax data.